Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Daratumumab (Primary) ; Bortezomib; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 09 May 2017 Planned End Date changed from 1 Mar 2022 to 1 Aug 2022.
- 09 May 2017 Planned primary completion date changed from 20 Jan 2020 to 1 Aug 2022.
- 20 Feb 2017 Planned End Date changed from 1 Jan 2020 to 1 Mar 2022.